The Effects of Beinaglutide on Obesity and Related Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Publisher



Poshtdar S^{1, 2} ; Rohani P³ ; Ahrabi A^{2, 4} ; Panahi N⁵ ; Sohouli MH³ Show Affiliations
Source: Expert Review of Endocrinology and Metabolism Published:2025

Abstract

Background: Considering the important role of obesity and related factors in different societies on increasing the burden of non-communicable diseases, in this review we will investigate the possible effects of Beinaglutide on these risk factors. Research design and methods: In order to identify all randomized controlled trials that investigated the effects of Beinaglutide on cardiometabolic factors, a systematic search was conducted in the original databases using predefined keywords until July 2024. The pooled weighted mean difference (WMD) and 95% confidence intervals were computed using the random-effects model. Results: A quantitative meta-analysis results from seven studies with 872 participants showed that Beinaglutide has a significant lowering effect on weight (WMD: -3.74 kg; 95% CI: -5.03, -2.45), body mass index (BMI) (WMD:-1.64 kg/m2; 95% CI: -2.10, -1.17), waist circumference (WC) (WMD: -3.19 cm; 95% CI: -4.65 to -1.73), triglyceride (TG) levels (WMD: -0.14 mmol/l with; 95% CI: -0.25, -0.04), and systolic blood pressure (SBP) (WMD: -1.76 mm/Hg; 95% CI: -2.61, -0.91). In addition, body weight loss was greater in doses < 0.4 mg compared to doses ≥ 0.4 mg. Conclusions: The results of this meta-analysis show that Beinaglutide is effective in reducing parameters related to obesity, TG as well as SBP. © 2025 Informa UK Limited, trading as Taylor & Francis Group.